Unknown PHASE3 INTERVENTIONAL 2-arm NCT04844905

Adjunctive Ivermectin Mass Drug Administration for Malaria Control (MATAMAL)

Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial

Sponsor: Bandim Health Project

Conditions Hook Worm Lymphatic Filariasis Malaria,Falciparum Neglected Tropical Diseases Scabies Soil Transmitted Helminths Strongyloidiasis

Interventions Dihydroartemisinin-piperaquine Ivermectin Placebo

Updated 5 times since 2021 Last updated: Feb 22, 2022 Started: May 3, 2021 Primary completion: Mar 31, 2023 Completion: Aug 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hook Worm and Lymphatic Filariasis, this trial is ongoing. The trial is conducted by Bandim Health Project and has accumulated 5 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Mar 2024 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Mar 2022 — Mar 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
May 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bandim Health Project
Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau
London School of Hygiene and Tropical Medicine
Medical Research Council Unit, The Gambia
Ministerio de Saude Publica, Guinee-Bissau

Data source: London School of Hygiene and Tropical Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bissau, Guinea-Bissau